BMS gets FDA nod for ozanimod, but launch will be delayedBristol-Myers Squibb’s multiple sclerosis therapy ozanimod has been approved by the FDA right on schedule, but the company Share XBMS gets FDA nod for ozanimod, but launch will be delayedhttps://pharmaphorum.com/news/bms-gets-fda-nod-for-ozanimod-but-launch-will-be-delayed/
Celgene gets MS blockbuster-in-waiting ozanimod back on trackRegulators in the US and EU have formally started their review of Celgene’s oral drug ozanimod for multiple Share XCelgene gets MS blockbuster-in-waiting ozanimod back on trackhttps://pharmaphorum.com/news/celgene-gets-ms-blockbuster-in-waiting-ozanimod-back-on-track/
Ozanimod launch delayed by failures in FDA applicationThe launch of Celgene’s multiple sclerosis drug, ozanimod, will be delayed after the company failed to submit key Share XOzanimod launch delayed by failures in FDA applicationhttps://pharmaphorum.com/news/ozanimod-launch-delayed-by-failures-in-fda-application/
